Pittsburgh Mayor Bob O'Connor's doctors are set to detail his treatment at a news conference this morning, and to explain his longer-than-hoped stay at UPMC Shadyside and a delay in administration of a second anti-cancer drug.

The mayor was originally scheduled to start on Temodar, a chemotherapy pill, yesterday. It was to be used in an experimental combination with the methotrexate he got eight days ago.

Doctors postponed giving the Temodar, according to a statement issued by the University of Pittsburgh Medical Center, which also reported that doctors are reducing Mr. O'Connor's intake of medication and monitoring his response.

Mayoral spokesman Dick Skrinjar said the doctors still plan to use Temodar eventually. He said they would provide specifics tomorrow, including information on whether the mayor is still expected to get a second methotrexate dose next week, as had been planned.

Mr. Skrinjar said the mayor did not sign a city contract with the Pittsburgh Downtown Partnership allowing wireless Internet antennae Downtown, as was planned, because staff did not take it to him, but that the signing might occur today.

He said the mayor has ordered his staff to keep track of all cards, letters and gifts he receives, so thank-you cards can be sent.

The mayor suffers from primary central nervous system lymphoma. His doctors have said that there has been a marked and unexplained increase in diagnoses of that cancer, though it is still a rare condition.

The Western Pennsylvania and West Virginia chapter of The Leukemia & Lymphoma Society issued a release saying the mayor's diagnosis shows that the search for a cure for the condition must be intensified.

"Mayor O'Connor's diagnosis is a reinforcement to our community on the importance of continuing the fight until a cure is found for all cancers and we ask everyone to support cancer research," chapter Executive Director George Omiros said in the release. "The thousands of patients whom we serve in our area know that it is research that provides treatment and cures."